Raynaud's phenomenon secondary to erenumab in a patient with chronic migraine
oleh: Agaath Hedina Manickam, Alina Buture, Esther Tomkins, Martin Ruttledge
| Format: | Article |
|---|---|
| Diterbitkan: | Wiley 2021-08-01 |
Deskripsi
Abstract Raynaud's phenomenon is a rare side effect of CGRP monoclonal antibodies. These molecular treatments are a relatively new class of drugs for the prevention of migraine. It is likely that we will see this side effect more often in the future. Patients with a background of Raynaud's phenomenon may experience worsening of their symptoms if started on these treatments.